N-{7-[(6-methoxyquinolin-8-yl)amino]-3-aza-2-oxooctyl}carbamic acid tert-butyl ester | 737004-36-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-{7-[(6-methoxyquinolin-8-yl)amino]-3-aza-2-oxooctyl}carbamic acid tert-butyl ester
• CAS: 737004-36-3
• 化学式: C₂₂H₃₂N₄O₄
• 分子量: 416.52
• InChiKey: UXGAAJAESDBISR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.46
• 重原子数：
  30.0
• 可旋转键数：
  9.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  101.58
• 氢给体数：
  3.0
• 氢受体数：
  6.0

反应信息

• 作为反应物：
  描述：

  N-{7-[(6-methoxyquinolin-8-yl)amino]-3-aza-2-oxooctyl}carbamic acid tert-butyl ester 在 三乙胺 、 三氟乙酸 作用下， 以 甲醇 为溶剂， 反应 25.0h， 生成
  参考文献：
  名称：

  A new procedure for N1-alkylation of imidazolidin-4-ones and its NMR characterization

  摘要：

  N-1-unsubstituted imidazolidin-4-ones of primaquine (PQ) can be stabilized by N-1-alkylation under basic conditions. Here we report the development, with our conditions, of peptidomimetic derivatives of PQ with L-amino acid and alkyl derivatives. The new derivatives represent potential new therapeutics for use against protozoan parasites, through enzymatic protection of aminopeptidases. (C) 2016 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.molstruc.2016.07.005
• 作为产物：
  描述：

  BOC-甘氨酸 、 伯氨喹 在 1-羟基苯并三唑 、 三乙胺 、 N,N'-二异丙基碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 生成 N-{7-[(6-methoxyquinolin-8-yl)amino]-3-aza-2-oxooctyl}carbamic acid tert-butyl ester
  参考文献：
  名称：

  伯氨喹的咪唑啉丁-4-酮拟肽衍生物：合成和抗疟活性。

  摘要：

  描述了在与母体药物偶联的二肽主链的C末端含有五元环的伯氨喹的咪唑烷二-4-酮衍生物的合成。这些拟肽衍生物对抗氯喹的恶性疟原虫菌株具有活性，并抑制了伯氏疟原虫的孢子周期的发展，影响了蚊子中肠内卵囊的出现。由于N（1）的酰化作用，新型的咪唑烷基-4-酮在人血浆和pH 7.4缓冲液中都极为稳定。因此，衍生自二肽基8-氨基喹啉的“内部”咪唑啉丁-4-酮代表了抗疟疾结构-活性关系中的一个新条目。

  DOI：

  10.1016/j.bmcl.2008.05.076

文献信息

• Primaquine dipeptide derivatives bearing an imidazolidin-4-one moiety at the N-terminus as potential antimalarial prodrugs
  作者：Nuno Vale、Fátima Nogueira、Virgílio E. do Rosário、Paula Gomes、Rui Moreira

  DOI：10.1016/j.ejmech.2009.01.018

  日期：2009.6

  Primaquine dipeptide derivatives bearing an imidazolidin-4-one moiety at the N-terminus were synthesized and evaluated as potential transmission-blocking antimalarial prodrugs. All compounds were hydrolyzed to the parent dipeptide derivative of primaquine in neutral and basic solutions, with half lives ranging from 0.7 to 31 h at 37 °C, depending on the nature of the substituents present in the imidazolidin-4-one

  合成了在N-末端带有咪唑烷基-4-酮部分的伯氨喹二肽衍生物，并将其评估为潜在的阻断传导的抗疟原药。所有化合物均在中性和碱性溶液中水解为伯氨喹的母体二肽衍生物，其半衰期在37°C下为0.7至31 h，具体取决于咪唑烷酮-4-one部分和烷基中存在的取代基的性质。 C端氨基酸直接偶联至伯氨喹。使用由伯氏疟原虫，BalbC小鼠和按蚊按蚊组成的模型研究了所选化合物的抗疟活性蚊子。由丙氨酸-丙氨酸伯氨喹和丙酮衍生的咪唑啉丁-4-酮比伯氨喹更有效地减少了感染向蚊子的传播，这表现为蚊子中肠中的卵囊数量显着减少，分别为10和50μmol/与对照相比，kg。
• Novel Potent Metallocenes against Liver Stage Malaria
  作者：Joana Matos、Filipa P. da Cruz、Élia Cabrita、Jiri Gut、Fátima Nogueira、Virgílio E. do Rosário、Rui Moreira、Philip J. Rosenthal、Miguel Prudêncio、Paula Gomes

  DOI：10.1128/aac.05345-11

  日期：2012.3

  Novel conjugates of the antimalarial drug primaquine (compound 1) with ferrocene, named primacenes, have been synthesized and screened for their activities against blood stage and liver stage malaria in vitro and host-vector transmission in vivo . Both transmission-blocking and blood-schizontocidal activities of the parent drug were conserved only in primacenes bearing a basic aliphatic amine group. Liver stage activity did not require this structural feature, and all metallocenes tested were comparable to or better than primaquine in this regard. Remarkably, the replacement of primaquine's aliphatic chain by hexylferrocene, as in compound 7, led to a ∼45-fold-higher level activity against liver stage parasitemia than that of primaquine.

  摘要 合成了抗疟药物伯氨喹（化合物 1）与二茂铁的新型共轭物，命名为二茂铁骁悉，并筛选了其对血期和肝期疟疾的活性。 体外 和宿主-病媒传播 体内 .母体药物的传播阻断和血吸虫杀灭活性只有在含有碱性脂肪胺基团的原烯中才得以保留。肝脏阶段的活性并不需要这一结构特征，所有测试过的茂金属在这方面都与伯氨喹相当或优于伯氨喹。值得注意的是，用二茂铁己基取代伯氨喹的脂肪链（如化合物 7），对肝阶段寄生虫血症的活性比伯氨喹高出 45 倍。
• Synthesis of imidazolidin-4-one and 1H-imidazo[2,1-a]isoindole-2,5(3H,9bH)-dione derivatives of primaquine: scope and limitations
  作者：Paula Gomes、Maria João Araújo、Manuela Rodrigues、Nuno Vale、Zélia Azevedo、Jim Iley、Paula Chambel、José Morais、Rui Moreira

  DOI：10.1016/j.tet.2004.04.077

  日期：2004.6

  The synthesis of imidazolidin-4-one derivatives of primaquine as potential antimalarial agents is described. The target compounds were synthesized in three steps: (i) condensation of (±)-primaquine with Nα-protected amino acids, (ii) removal of the Nα-protecting group, and (iii) reaction of the N-acylprimaquine with a carbonyl compound: acetone, three cyclic ketones and veratraldehyde. Using 2-formylbenzoic

  描述了伯氨喹的咪唑啉丁-4-酮衍生物作为潜在的抗疟药的合成。在三个步骤中合成的目标化合物：（ⅰ）的缩合（±）-primaquine用N α -保护的氨基酸，（ⅱ）除去N-的α保护基团，和（iii）的N acylprimaquine与反应羰基化合物：丙酮，三个环酮和藜芦醛。在得到第三步骤，使用2-甲酰基苯甲酸1 H ^ -咪唑并[2,1-一个]异吲哚-2,5（3 ħ，9B ħ） -二酮。分离出的所有产物均具有良好的收率。咪唑啉丁-4-酮是所有可能的非对映异构体的等量混合物，而1 H-咪唑并[2,1-以立体选择性的方式产生]异吲哚-2,5（3 H，9b H）-二酮。化合物在pH 7.4缓冲液中水解非常缓慢（t 1/2 5–30 d），释放出伯氨喹。这些伯氨喹衍生物正在接受生物学检测，其抗疟活性的初步结果令人鼓舞。
• Amino acids as selective acylating agents: regioselective N1-acylation of imidazolidin-4-one derivatives of the antimalarial drug primaquine
  作者：Nuno Vale、Joana Matos、Rui Moreira、Paula Gomes

  DOI：10.1016/j.tet.2008.09.058

  日期：2008.12

  The acylation of bioactive primaquine-based imidazolidin-4-ones was studied using Nα-Boc-protected glycine as acylating agent. Two synthesis routes, eight different coupling methods and seven distinct solvents were compared. Mild carbodiimide-based couplings on high dielectric constant solvents such as DMF or MeCN increased acylation yields, whereas alcohols inhibited carbodiimide-mediated acylations

  使用的生物活性基于伯-咪唑烷-4-酮的酰化进行了研究Ñ α -Boc保护的甘氨酸作为酰化剂。比较了两种合成路线，八种不同的偶联方法和七种不同的溶剂。在高介电常数溶剂（例如DMF或MeCN）上基于碳二亚胺的轻度偶联提高了酰化收率，而醇类则抑制了碳二亚胺介导的酰化反应。合成目标的实现受限于咪唑烷基-4-酮环取代基R 1，R 2和R 3的大小，但诉诸于MW辅助合成可以克服此类障碍，尽管反应收率非常适中。涉及所用Boc保护的氨基酸的所有反应均具有区域选择性，而与所采用的反应条件无关。相比之下，咪唑烷丁-4-酮的区域选择性乙酰化只能通过非常温和的偶联程序来实现。
• Imidazoquines as Antimalarial and Antipneumocystis Agents
  作者：Nuno Vale、Miguel Prudêncio、Catarina A. Marques、Margaret S. Collins、Jiri Gut、Fátima Nogueira、Joana Matos、Philip J. Rosenthal、Melanie T. Cushion、Virgílio E. do Rosário、Maria M. Mota、Rui Moreira、Paula Gomes

  DOI：10.1021/jm900738c

  日期：2009.12.10

  Peptidomimetic imidazolidin-4-one derivatives of primaquine (imidazoquines) recently displayed in vitro activity against blood schizonts of a chloroquine-resistant strain of Plasmodium falciparum. Preliminary studies with a subset of such imidazoquines showed them to both block transmission of P. berghei malaria front mouse to mosquito and be highly stable toward hydrolysis at physiological conditions. This prompted Lis to have deeper insight into the activity of imidazoquines against both Plasmodia and Pneumocystis carinii, on which primaquine is also active. Full assessment of the in vivo transmission-blocking activity of imidazoquines, in vitro tissue-schizontocidal activity on P. berghei-infected hepatocytes, and in vitro anti-P. carinii activity is now reported. All compounds were active in these biological assays, with generally lower activity than the parent drug. However, imidazoquines' stability against both oxidative deamination and proteolytic degradation suggest that they will probably have higher oral bioavailability and lower hematotoxicity than primaquine, which might translate into higher therapeutic indexes.